CSL Ltd Annual Report 2019

4 At CSL, our deep commitment to delivering on our promise to patients is what unites us as a global biotech leader. As we continue to grow, our Patient Focus has never been more important. CSL is the world’s fifth largest biotechnology company, and our more than 25,000 employees are driven by our promise to discover, develop and deliver lifesaving and life-enhancing medicines to patients across the world. We are successfully executing our strategy by: – – focusing on patients at the centre of everything we do; – – valuing people as our greatest asset; and – – fostering a culture of innovation across the organisation. Rapid changes are occurring in science, medicine, technology and the markets in which we operate. These dynamics will impact both CSL and how we care for patients in the future. Yet one constant will remain: Our Patient Focus. As our business continues to grow, saving people’s lives and protecting public health across the globe is fundamental to our strategy. Our talented people and innovative culture will advance our sustainable growth to help us meet the needs and demands of patients into 2030 and beyond. More on CSL.c om More on CSL.com More on CSL.com United Nations Sustainable Development Goals Visit CSL.com (corporateresponsibility.csl.com/approach ) for how CSL supports the United Nations Sustainable Development Goals, specifically: CSL Limited Annual Report 2019 10 CSL Strategy